Al-Sawaf O, Stumpf J, Zhang C, et al. Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial. N Engl J Med. 2025; DOI: 10.1056/NEJMoa2515458.
Brown JR, et al. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2023;388(4):319-332.
Byrd JC, et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results From a First Randomized Phase III Trial. J Clin Oncol. 2021;39(31):3441-3452.
Eichhorst B, et al. First-Line Venetoclax Combinations in Fit Patients with CLL. N Engl J Med. 2023;388(19):1739-1751.
Eichhorst B, Ghia P, Bosch F, Clifford R, Gregor M, Guieze R, Kater AP, Niemann CU, Pospisilova S, Robak T, Schuh A, Stamatopoulos K, Tadmor T, York N. EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation. HemaSphere. 2026;10(6):e70403. doi:10.1002/hem3.70403.
Fischer K, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019;380(23):2225-2236.
Kater AP, et al. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia (GLOW). NEJM Evid. 2022;1(7):EVIDoa2200006.
Langerbeins P, et al. Ibrutinib versus Placebo in patients with asymptomatic, high-risk early-stage chronic lymphocytic leukemia (CLL12): a randomized, double-blind, Placebo-controlled, phase 3 study. Lancet Oncol. 2022;23(11):1393-1404.
Mato AR, et al. Pirtobrutinib in covalent BTK-inhibitor-pretreated chronic lymphocytic leukemia (BRUIN): a phase 1/2 study. Lancet. 2021;397(10288):1892-1902.
Seymour JF, et al. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018;378(24):2265-2277.
Shanafelt TD, et al. Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med. 2019;381(5):432-443.
Sharman JP, et al. Acalabrutinib with or without Obinutuzumab versus Chlorambucil plus Obinutuzumab for Untreated Chronic Lymphocytic Leukemia (ELEVATE-TN). Lancet. 2020;395(10232):1278-1291.
Simon F, et al. Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial. Blood. 2025 Dec 25;146(26):3153-3162
Tam CS, et al. Zanubrutinib versus bendamustine plus rituximab in patients with untreated chronic lymphocytic leukaemia (SEQUOIA): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(8):1031-1043.
Woyach JA, et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018;379(26):2517-2528.